MONTREAL, CANADA and LES ULIS, FRANCE–(Marketwired – Aug 6, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, and LFB S.A., a biopharmaceutical Group focused on innovative therapeutics for serious and rare diseases, today announced that Knight’s New Drug Submission (NDS) has been accepted for review by Health Canada for ATryn® [Antithrombin (Recombinant)] for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.
“ATryn®, an innovative treatment for patients with hereditary antithrombin deficiency, marks Knight’s first submission to Health Canada”, said Jonathan Ross Goodman, President and CEO of Knight. “ATryn® is approved for sale in both the US and Europe and touches the lives of patients with hereditary antithrombin deficiency. We look forward to bringing this important treatment option to Canadian patients”.
“This is another important milestone for ATryn®. We look forward to working with Knight and Health Canada to ensure ATryn® will become available to Canadian patients”, said Christian Béchon, Chairman and Chief Executive Officer, LFB S.A.
Knight received the rights to commercialize ATryn® in Canada through its acquisition of Orphan Canada’s assets in September 2014.
About ATryn®
ATryn® is a recombinant human antithrombin. If approved, ATryn® would be used for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. ATryn®, is the first and only recombinant antithrombin concentrate. ATryn® received EMA approval in 2006 and FDA approval in 2009, for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com.
About LFB
LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care. Number one in France and 6th worldwide in the field of plasma-derived medicines, LFB Group is also one of the leading European companies in the development and production of proteins and innovative treatment derived from biotechnology. With a sustained research effort, LFB Group is implementing a growth strategy focused on developing its international activities. LFB Group currently sells products in over 40 countries worldwide and achieved a total turnover of 501.9 MEUR in 2014. LFB Group counts 2016 employees worldwide.
Forward-Looking Statement
This document contains forward-looking statements for the Company and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in the Company’s Annual Report and in the Company’s Annual Information Form for the year ended December 31, 2014. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.
